AbbVie, Halozyme Collaborate
News Jun 04, 2015
Under their global collaboration and licensing agreement, AbbVie has agreed to pay Halogen an initial $23 million upfront, followed by payments tied to achieving development, regulatory, and sales-based milestones, totaling about $130 million for each of up to nine collaboration targets.
In addition, AbbVie agreed to pay Halozyme tiered royalties if products under the collaboration are commercialized.
ENHANZE™ is based on a recombinant human hyaluronidase or rHuPH20 that aids in the dispersion and absorption of other injected therapeutic drugs by temporarily degrading hyaluronan.
AbbVie reasons that the platform may enable more rapid delivery of injectable medications through subcutaneous delivery. The platform also holds potential for benefiting users of subcutaneous biologics by reducing the need for multiple injections.
Helen Torley, M.B., Ch.B., Halozyme’s president and CEO, said in a statement that AbbVie joins several biopharma giants in partnering with Halozyme to develop new formulations of their drugs. These companies include Baxter International, Johnson & Johnson’s Janssen Biotech, Pfizer, and Roche.
Tiny Particles Carry Tumor Shrinking Drugs into the BrainNews
MIT researchers have now devised a new drug-delivering nanoparticle that could offer a better way to treat glioblastoma. The particles, which carry two different drugs, are designed so that they can easily cross the blood-brain barrier and bind directly to tumor cells.READ MORE
Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous SclerosisNews
Addressing a critical issue for people with a genetic disorder called tuberous sclerosis complex (TSC), doctors reported that a skin cream containing rapamycin significantly reduced the disfiguring facial tumors affecting more than 90 percent of people with the condition.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018